<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34990001</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1699-3055</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title>
          <ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>1014</StartPage>
          <EndPage>1032</EndPage>
          <MedlinePgn>1014-1032</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-021-02763-x</ELocationID>
        <Abstract>
          <AbstractText>Esophageal cancer is a complex gastrointestinal malignancy with an extremely poor outcome. Approximately 80% of cases of this malignancy in Asian countries including India are of squamous cell origin, termed Esophageal Squamous Cell Carcinoma (ESCC).The five-year survival rate in ESCC patients is less than 20%. Neo-adjuvant chemo-radiotherapy (NACRT) followed by surgical resection remains the major therapeutic strategy for patients with operable ESCC. However, resistance to NACRT and local recurrence after initial treatment are the leading cause of dismal outcomes in these patients. Therefore, an alternative strategy to promote response to the therapy and reduce the post-operative disease recurrence is highly needed. At the molecular level, wide variations have been observed in tumor characteristics among different populations, nevertheless, several common molecular features have been identified which orchestrate disease progression and clinical outcome in the malignancy. Therefore, determination of candidate molecular pathways for targeted therapy remains the mainstream idea of focus in ESCC research. In this review, we have discussed the key signaling pathways associated with ESCC, i.e., Notch, Wnt, and Nrf2 pathways, and their crosstalk during disease progression. We further discuss the recent developments of novel agents to target these pathways in the context of targeted cancer therapy. In-depth research of the signaling pathways, gene signatures, and a combinatorial approach may help in discovering targeted therapy for ESCC.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Kadian</LastName>
            <ForeName>L K</ForeName>
            <Initials>LK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Arora</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prasad</LastName>
            <ForeName>C P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology (Lab), Dr. B. R. Ambedkar-IRCH, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pramanik</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dr. B. R. Ambedkar-IRCH, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chauhan</LastName>
            <ForeName>S S</ForeName>
            <Initials>SS</Initials>
            <Identifier Source="ORCID">0000-0002-4796-5171</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India. s_s_chauhan@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Clin Transl Oncol</MedlineTA>
        <NlmUniqueID>101247119</NlmUniqueID>
        <ISSNLinking>1699-048X</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077277" MajorTopicYN="Y">Esophageal Squamous Cell Carcinoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Esophageal squamous carcinoma</Keyword>
        <Keyword MajorTopicYN="N">NACT</Keyword>
        <Keyword MajorTopicYN="N">Notch</Keyword>
        <Keyword MajorTopicYN="N">Nrf2</Keyword>
        <Keyword MajorTopicYN="N">Signaling pathways</Keyword>
        <Keyword MajorTopicYN="N">Targeted therapy</Keyword>
        <Keyword MajorTopicYN="N">Wnt</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>12</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34990001</ArticleId>
        <ArticleId IdType="doi">10.1007/s12094-021-02763-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s12094-021-02763-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24039351</ArticleId>
            <ArticleId IdType="pmc">3769895</ArticleId>
            <ArticleId IdType="doi">10.3748/wjg.v19.i34.5598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klingelhöfer D, Zhu Y, Braun M, Brüggmann D, Schöffel N, Groneberg DA. A world map of esophagus cancer research: a critical accounting. J Transl Med. 2019;17:150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31077194</ArticleId>
            <ArticleId IdType="pmc">6511204</ArticleId>
            <ArticleId IdType="doi">10.1186/s12967-019-1902-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H-Z, Jin G-F, Shen H-B. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chinese J Cancer BioMed Central. 2012;31:281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5732/cjc.011.10390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Dhingra S. Pathology of esophageal cancer and Barrett’s esophagus. Ann Cardiothorac Surg. 2017;6:99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28446998</ArticleId>
            <ArticleId IdType="pmc">5387146</ArticleId>
            <ArticleId IdType="doi">10.21037/acs.2017.03.06</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaidi N, Kelly RJ. The management of localized esophageal squamous cell carcinoma: western approach. Chin J Cancer. 2017;6:46.</Citation>
        </Reference>
        <Reference>
          <Citation>Mahoney JL, Condon RE. Adenocarcinoma of the esophagus. Ann Surg. 1987;205:557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2437870</ArticleId>
            <ArticleId IdType="pmc">1493043</ArticleId>
            <ArticleId IdType="doi">10.1097/00000658-198705000-00015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haque W, Verma V, Butler EB, Teh BS. Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. J Gastrointest Oncol. 2018;9:80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29564174</ArticleId>
            <ArticleId IdType="pmc">5848043</ArticleId>
            <ArticleId IdType="doi">10.21037/jgo.2017.09.12</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC <sub>50</sub> 10 randomized clinical trial. JAMA Surg. 2021;156:721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34160577</ArticleId>
            <ArticleId IdType="pmc">8223138</ArticleId>
            <ArticleId IdType="doi">10.1001/jamasurg.2021.2373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30171414</ArticleId>
            <ArticleId IdType="doi">10.1007/s10388-018-0642-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16822992</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa055531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet. 2019;393:1948–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)32557-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33789008</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa2032125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1:466–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12496471</ArticleId>
            <ArticleId IdType="doi">10.4161/cbt.1.5.159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci U S A. 2003;100:7638–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12794186</ArticleId>
            <ArticleId IdType="pmc">164639</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1230693100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19379690</ArticleId>
            <ArticleId IdType="pmc">2827930</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2009.03.045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng AP. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15472075</ArticleId>
            <ArticleId IdType="doi">10.1126/science.1102160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pei J, Wang B. Notch-1 promotes breast cancer cells proliferation by regulating LncRNA GAS5. Int J Clin Exp Med. 2015;8:14464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26550436</ArticleId>
            <ArticleId IdType="pmc">4613121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J-X, Han Y-P, Bai C, Li Q. Notch1/3 and p53/p21 are a potential therapeutic target for APS-induced apoptosis in non-small cell lung carcinoma cell lines. Int J Clin Exp Med. 2015;8:12539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26550164</ArticleId>
            <ArticleId IdType="pmc">4612849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36:319–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31526760</ArticleId>
            <ArticleId IdType="pmc">6853173</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.08.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao W-Q. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res. 2001;61:7291–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11585768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003;63:8323–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14678992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3:565–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12842085</ArticleId>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00140-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene. 2005;24:6333–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15940249</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.onc.1208783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004;64:7787–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520184</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-1446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer. 2005;93:709–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16136053</ArticleId>
            <ArticleId IdType="pmc">2361628</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjc.6602719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban J, Aryee DN, Fourtouna A, Van Der Ent W, Kauer M, Niedan S, et al. Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res. 2014;74:6578–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25281719</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-1736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadian LK, Gulshan G, Ahuja P, Singhal G, Sharma S, Nanda S, et al. Aberrant promoter methylation of NOTCH1 and NOTCH3 and its association with cervical cancer risk factors in North Indian population. Am J Transl Res. 2020;12:2814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32655812</ArticleId>
            <ArticleId IdType="pmc">7344087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011;224:448–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21598247</ArticleId>
            <ArticleId IdType="doi">10.1002/path.2895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>dos Santos W, Sobanski T, de Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, et al. Mutation profiling of cancer drivers in Brazilian colorectal cancer. Sci Rep. 2019;9:13687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31548566</ArticleId>
            <ArticleId IdType="pmc">6757044</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-019-49611-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gan R-H, Wei H, Xie J, Zheng D-P, Luo E-L, Huang X-Y, et al. Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion. Cell Cycle. 2018;17:216–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29117785</ArticleId>
            <ArticleId IdType="doi">10.1080/15384101.2017.1395534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuramoto T, Goto H, Mitsuhashi A, Tabata S, Ogawa H, Uehara H, et al. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity. Mol Cancer Ther. 2012;11:2578–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22989420</ArticleId>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-12-0640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan X, Wu H, Xu H, Han N, Chu Q, Yu S, et al. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 2015;5:10338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25996086</ArticleId>
            <ArticleId IdType="pmc">4440529</ArticleId>
            <ArticleId IdType="doi">10.1038/srep10338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, et al. Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A. 2002;99:3788–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11891328</ArticleId>
            <ArticleId IdType="pmc">122602</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.062050599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou J, Li P, Lu F, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23289374</ArticleId>
            <ArticleId IdType="pmc">3544631</ArticleId>
            <ArticleId IdType="doi">10.1186/1756-8722-6-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Li Y, Kong D, Sarkar HF. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010;11:745–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20041844</ArticleId>
            <ArticleId IdType="pmc">3084452</ArticleId>
            <ArticleId IdType="doi">10.2174/138945010791170860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Y, Chen H, Zhang J, Chen Y, Wang M, Ma J, et al. Increased Notch signaling enhances radioresistance of malignant stromal cells induced by glioma stem/progenitor cells. PLoS ONE. 2015;10: e0142594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26599017</ArticleId>
            <ArticleId IdType="pmc">4657951</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0142594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA. 2006;103:9262–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16751266</ArticleId>
            <ArticleId IdType="pmc">1570422</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.0603371103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006;66:1517–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16452208</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109:2587–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24129237</ArticleId>
            <ArticleId IdType="pmc">3833225</ArticleId>
            <ArticleId IdType="doi">10.1038/bjc.2013.642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, et al. NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 2010;139:2113–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20801121</ArticleId>
            <ArticleId IdType="doi">10.1053/j.gastro.2010.08.040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yizhak K, Aguet F, Kim J, Hess J, Kübler K, Grimsby J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. 2019;364:eaaw026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaw0726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30602793</ArticleId>
            <ArticleId IdType="doi">10.1038/s41586-018-0811-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang J, Tan W, Ling Z, Xi R, Shao M, Chen M, et al. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun. 2017;8:15290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28548104</ArticleId>
            <ArticleId IdType="pmc">5477513</ArticleId>
            <ArticleId IdType="doi">10.1038/ncomms15290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362:911–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30337457</ArticleId>
            <ArticleId IdType="pmc">6298579</ArticleId>
            <ArticleId IdType="doi">10.1126/science.aau3879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012;2:899–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22877736</ArticleId>
            <ArticleId IdType="pmc">3473124</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y-B, Chen Z-L, Li J-G, Hu X-D, Shi X-J, Sun Z-M, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25151357</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.3076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lubin DJ, Mick R, Shroff SG, Stashek K, Furth EE. The notch pathway is activated in neoplastic progression in esophageal squamous cell carcinoma. Hum Pathol. 2018;72:66–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29137934</ArticleId>
            <ArticleId IdType="doi">10.1016/j.humpath.2017.11.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa R, Ishiguro H, Kimura M, Funahashi H, Wakasugi T, Ando T, et al. NOTCH1 expression predicts patient prognosis in esophageal squamous cell cancer. Eur Surg Res. 2013;51:101–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24217574</ArticleId>
            <ArticleId IdType="doi">10.1159/000355674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Li Y, Chen X. NOTCH and esophageal squamous cell carcinoma. Adv Exp Med Biol. 2021;1287:59–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33034026</ArticleId>
            <ArticleId IdType="pmc">7895477</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-55031-8_5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Fan H, Ma Y, Liang D, Huang R, Wang J, et al. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS ONE. 2013;8: e56141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23409141</ArticleId>
            <ArticleId IdType="pmc">3567068</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0056141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Xuan X, Pian L, Gao P, Xu H, Zheng Y, et al. Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial–mesenchymal transition through Snail. Tumor Biol. 2014;35:1193–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-013-1159-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Li Q, Liu F, Chen X, Liu B, Nesa EU, et al. Notch2 as a promising prognostic biomarker for oesophageal squamous cell carcinoma. Sci Rep. 2016;6:25722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27158037</ArticleId>
            <ArticleId IdType="pmc">4860585</ArticleId>
            <ArticleId IdType="doi">10.1038/srep25722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forghanifard MM, Moaven O, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol. 2012;19:743–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22006371</ArticleId>
            <ArticleId IdType="doi">10.1245/s10434-011-2074-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taleb S, Abbaszadegan MR, Moghbeli M, Roudbari NH, Forghanifard MM. HES1 as an independent prognostic marker in esophageal squamous cell carcinoma. Gastrointest Cancer. 2014;45:466–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12029-014-9648-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brennan K, Clarke RB. Combining Notch inhibition with current therapies for breast cancer treatment. Ther Adv Med Oncol. 2013;5:17–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23323144</ArticleId>
            <ArticleId IdType="pmc">3539271</ArticleId>
            <ArticleId IdType="doi">10.1177/1758834012457437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei W, Chua M-S, Grepper S, So S. Small molecule antagonists of Tcf4/β-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010;126:2426–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19662654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miele L, Miao H, Nickoloff BJ. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6:313–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16848722</ArticleId>
            <ArticleId IdType="doi">10.2174/156800906777441771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol. 2003;194:356–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12548555</ArticleId>
            <ArticleId IdType="doi">10.1002/jcp.10217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27:5124–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18758481</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2008.226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hecht A, Vleminckx K, Stemmler MP, Van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of β-catenin in vertebrates. EMBO J. 2000;19:1839–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10775268</ArticleId>
            <ArticleId IdType="pmc">302022</ArticleId>
            <ArticleId IdType="doi">10.1093/emboj/19.8.1839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar A, Chalamalasetty RB, Kennedy MW, Thomas S, Inala SN, Garriock RJ, et al. Zfp703 is a Wnt/β-catenin feedback suppressor targeting the β-Catenin/Tcf1 complex. Mol Cell Biol. 2016;36:1793–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27090637</ArticleId>
            <ArticleId IdType="pmc">4907093</ArticleId>
            <ArticleId IdType="doi">10.1128/MCB.01010-15</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19619488</ArticleId>
            <ArticleId IdType="pmc">2861485</ArticleId>
            <ArticleId IdType="doi">10.1016/j.devcel.2009.06.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23258168</ArticleId>
            <ArticleId IdType="doi">10.1038/nrc3419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27617575</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2016.304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bugter JM, Fenderico N, Maurice MM. Publisher Correction: Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2021;21:64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33149279</ArticleId>
            <ArticleId IdType="doi">10.1038/s41568-020-00316-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lannagan TRM, Lee YK, Wang T, Roper J, Bettington ML, Fennell L, et al. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut. 2019;68:684–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29666172</ArticleId>
            <ArticleId IdType="doi">10.1136/gutjnl-2017-315920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L-H, Xu H-T, Li Q-C, Jiang G-Y, Zhang X-P, Zhao H-Y, et al. Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer. Tumour Biol. 2013;34:749–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23192643</ArticleId>
            <ArticleId IdType="doi">10.1007/s13277-012-0604-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadian LK, Yadav R, Nanda S, Gulshan G, Sharma S, Yadav C. High-risk HPV infection modulates the promoter hypermethylation of APC, SFRP1, and PTEN in cervical cancer patients of North India. Mol Biol Rep. 2020;47:9725–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33230782</ArticleId>
            <ArticleId IdType="doi">10.1007/s11033-020-05960-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwong LN, Dove WF. APC and its modifiers in colon cancer. APC Proteins. 2009;656:85–106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4419-1145-2_8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, et al. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits.” Proc Natl Acad Sci USA. 2000;97:3352–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10737795</ArticleId>
            <ArticleId IdType="pmc">16243</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.97.7.3352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2188735</ArticleId>
            <ArticleId IdType="doi">10.1016/0092-8674(90)90186-I</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dow LE, O’Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell. 2015;161:1539–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26091037</ArticleId>
            <ArticleId IdType="pmc">4475279</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cell.2015.05.033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MA, Park J-H, Rhyu SY, Oh S-T, Kang W-K, Kim H-N. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer. 2014;14:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z, et al. Frizzled7 Promotes epithelial-to-mesenchymal transition and stemness via activating canonical Wnt/β-catenin pathway in gastric cancer. Int J Biol Sci. 2018;14:280–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29559846</ArticleId>
            <ArticleId IdType="pmc">5859474</ArticleId>
            <ArticleId IdType="doi">10.7150/ijbs.23756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boone JD, Arend RC, Johnston BE, Cooper SJ, Gilchrist SA, Oelschlager DK, et al. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest. 2016;96:249–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26658453</ArticleId>
            <ArticleId IdType="doi">10.1038/labinvest.2015.150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA. 2010;107:5136–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20194742</ArticleId>
            <ArticleId IdType="pmc">2841938</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.0911220107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farah O, Biechele S, Rossant J, Dufort D. Porcupine-dependent Wnt activity within the uterine epithelium is essential for fertility. Biol Reprod. 2017;97:688–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29036275</ArticleId>
            <ArticleId IdType="doi">10.1093/biolre/iox119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of β-catenin in mice. Genes Dev. 2008;22:2308–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18765787</ArticleId>
            <ArticleId IdType="pmc">2749675</ArticleId>
            <ArticleId IdType="doi">10.1101/gad.1686208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J. 1999;18:5931–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10545105</ArticleId>
            <ArticleId IdType="pmc">1171659</ArticleId>
            <ArticleId IdType="doi">10.1093/emboj/18.21.5931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devereux TR, Stern MC, Flake GP, Yu MC, Zhang ZQ, London SJ, et al. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog. 2001;31:68–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11429783</ArticleId>
            <ArticleId IdType="doi">10.1002/mc.1041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017;30:1032–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28281553</ArticleId>
            <ArticleId IdType="pmc">5493522</ArticleId>
            <ArticleId IdType="doi">10.1038/modpathol.2017.15</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3:36–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14739782</ArticleId>
            <ArticleId IdType="doi">10.4161/cbt.3.1.561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C-C, Prior J, Piwnica-Worms D, Bu G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA. 2010;107:5136–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20194742</ArticleId>
            <ArticleId IdType="pmc">2841938</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.0911220107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011;30:4437–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21532620</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2011.145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin S-Y, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, et al. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000;97:4262–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10759547</ArticleId>
            <ArticleId IdType="pmc">18221</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.060025397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T, et al. Rap1 stabilizes β-catenin and enhances β-catenin–dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2010;16:65–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028760</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-1122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer. 2004;101:1345–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15316903</ArticleId>
            <ArticleId IdType="doi">10.1002/cncr.20518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, et al. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. 2015;6:23720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26125441</ArticleId>
            <ArticleId IdType="pmc">4695147</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.4690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer. 2007;96:646–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17245340</ArticleId>
            <ArticleId IdType="pmc">2360041</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjc.6603579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17363569</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-3369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14695408</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa030847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306667</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa040258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Yan H-X, Chen L, Liu Q, He Y-Q, Yu L-X, et al. Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18519688</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, et al. Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 2009;100:1647–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19401692</ArticleId>
            <ArticleId IdType="pmc">2696759</ArticleId>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Yang Y, Jiang M, Huang SX, Zhang W, Al Alam D, et al. 3D modeling of esophageal development using human PSC-derived basal progenitors reveals a critical role for Notch signaling. Cell Stem Cell. 2018;23:516-529.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30244870</ArticleId>
            <ArticleId IdType="pmc">6282026</ArticleId>
            <ArticleId IdType="doi">10.1016/j.stem.2018.08.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75</Citation>
        </Reference>
        <Reference>
          <Citation>Deng F, Zhou K, Cui W, Liu D, Ma Y. Clinicopathological significance of wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8:3045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26045816</ArticleId>
            <ArticleId IdType="pmc">4440125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Zhou X, Xue L, Quan L, Wang Y, Zhou C, et al. Accumulation of cytoplasmic β-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: Immunohistochemical study. Pathol Int. 2005;55:310–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15943787</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1440-1827.2005.01840.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long A, Giroux V, Whelan KA, Hamilton KE, Tétreault M-P, Tanaka K, et al. WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma. Carcinogenesis. 2015;36:598–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25795715</ArticleId>
            <ArticleId IdType="pmc">4498148</ArticleId>
            <ArticleId IdType="doi">10.1093/carcin/bgv025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Yan Y, Ma W, Wu S. Knockdown of frizzled-7 inhibits cell growth and metastasis and promotes chemosensitivity of esophageal squamous cell carcinoma cells by inhibiting Wnt signaling. Biochem Biophys Res Commun. 2017;490:1112–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28669726</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.06.185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS, Rustgi AK. Wnt-1 but not epidermal growth factor induces β-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002;62:277–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagai Y, Watanabe M, Ishikawa S, Karashima R, Kurashige J, Iwagami S, et al. Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res. 2011;31:991–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21498727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oguma J, Ozawa S, Kazuno A, Nitta M, Ninomiya Y, Kajiwara H. Wnt3a expression is associated with poor prognosis of esophageal squamous cell carcinoma. Oncology Lett. 2018;15:3100–8.</Citation>
        </Reference>
        <Reference>
          <Citation>de Souza-Santos PT, Lima SCS, Nicolau-Neto P, Boroni M, Da Costa NM, Brewer L, et al. Mutations, differential gene expression, and chimeric transcripts in esophageal squamous cell carcinoma show high heterogeneity. Transl Oncol. 2018;11:1283–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30172240</ArticleId>
            <ArticleId IdType="pmc">6121831</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tranon.2018.08.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Liu S, Zhang W, Zhu H, Zhou X, Zhou C, et al. Aberrant activation of Wnt/β-catenin pathway in esophageal squamous cell carcinoma (ESCC): evidence of FRAT1 overexpression. AACR 2006;629.</Citation>
        </Reference>
        <Reference>
          <Citation>Makino T, Yamasaki M, Takemasa I, Takeno A, Nakamura Y, Miyata H, et al. Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Surg Oncol. 2009;16:2058–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-009-0476-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Li W, Liu S, Su Y, Han G, Xu C, et al. Interleukin-23 promotes the epithelial-mesenchymal transition of oesophageal carcinoma cells via the Wnt/β-catenin pathway. Sci Rep. 2015;5:8604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25721268</ArticleId>
            <ArticleId IdType="pmc">4342574</ArticleId>
            <ArticleId IdType="doi">10.1038/srep08604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Su Y, Zhu H, Wang X, Li X, Dai C, et al. Interleukin-23 receptor signaling mediates cancer dormancy and radioresistance in human esophageal squamous carcinoma cells via the Wnt/Notch pathway. J Mol Med. 2019;97:177–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30483821</ArticleId>
            <ArticleId IdType="doi">10.1007/s00109-018-1724-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Y-F, Yong X, Tang B, Qin Y, Zhang J-W, Zhang D, et al. Notch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets. Int J Oncol. 2016;48:437–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26648421</ArticleId>
            <ArticleId IdType="doi">10.3892/ijo.2015.3280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19182219</ArticleId>
            <ArticleId IdType="pmc">2679427</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.R900010200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J, Xiong Z, Huang C, Li J, Yang W, Han Y, et al. Hyperactivity of the transcription factor Nrf2 causes metabolic reprogramming in mouse esophagus. J Biol Chem. 2019;294:327–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30409900</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.RA118.005963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed SMU, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta. 2017;1863:585–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2016.11.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol. 2017;11:543–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28104575</ArticleId>
            <ArticleId IdType="pmc">5239825</ArticleId>
            <ArticleId IdType="doi">10.1016/j.redox.2017.01.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ. Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget. 2013;4:1130–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24029073</ArticleId>
            <ArticleId IdType="pmc">3787145</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.1181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Fang Y, Li W, Orlando RC, Shaheen N, Chen XL. NFkB and Nrf2 in esophageal epithelial barrier function. Tissue Barriers. 2013;1: e27463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24790804</ArticleId>
            <ArticleId IdType="pmc">3943848</ArticleId>
            <ArticleId IdType="doi">10.4161/tisb.27463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma S, Paiboonrungruan C, Yan T, Williams KP, Major MB, Chen XL. Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci. 2018;1434:164–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29752726</ArticleId>
            <ArticleId IdType="pmc">6230513</ArticleId>
            <ArticleId IdType="doi">10.1111/nyas.13681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storz L, Walther P, Chemnitzer O, Lyros O, Niebisch S, Mehdorn M, et al. Nrf2/Keap1-pathway activation and reduced susceptibility to chemotherapy treatment by acidification in esophageal adenocarcinoma cells. Cancers (Basel). 2021;13:2806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13112806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Hu Y, Fang Y, Djukic Z, Yamamoto M, Shaheen NJ, et al. Nrf2 deficiency impairs the barrier function of mouse esophageal epithelium. Gut. 2014;63:711–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23676441</ArticleId>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-303731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohkoshi A, Suzuki T, Ono M, Kobayashi T, Yamamoto M. Roles of Keap1-Nrf2 system in upper aerodigestive tract carcinogenesis. Cancer Prev Res (Phila). 2013;6:149–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-12-0401-T</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin D-C, Dinh HQ, Xie J-J, Mayakonda A, Silva TC, Jiang Y-Y, et al. Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas. Gut. 2018;67:1769–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28860350</ArticleId>
            <ArticleId IdType="doi">10.1136/gutjnl-2017-314607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia. 2011;13:864–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21969819</ArticleId>
            <ArticleId IdType="pmc">3182278</ArticleId>
            <ArticleId IdType="doi">10.1593/neo.11750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Cancer Genome Atlas Research Network - 2017 - Integrated genomic characterization of oesophageal.pdf [Internet]. [cited 2019 Feb 6]. Available from: https://www.nature.com/articles/nature20805.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Cui Y, Chen H, Xi R, Cui H, Zhao Y, Xu E, et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 2020;30:902–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32398863</ArticleId>
            <ArticleId IdType="pmc">7608103</ArticleId>
            <ArticleId IdType="doi">10.1038/s41422-020-0333-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Jiao Q, Kong L, Yu J, Fang A, Li M, et al. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer. 2018;9:726–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29675925</ArticleId>
            <ArticleId IdType="pmc">5983206</ArticleId>
            <ArticleId IdType="doi">10.1111/1759-7714.12640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva-Islas CA, Maldonado PD. Canonical and non-canonical mechanisms of Nrf2 activation. Pharmacol Res. 2018;134:92–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29913224</ArticleId>
            <ArticleId IdType="doi">10.1016/j.phrs.2018.06.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J. 2011;278:3256–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21794094</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2011.08275.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013;85:705–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23219527</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bcp.2012.11.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Mahdi A, et al. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res. 2017;77:2881–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28416489</ArticleId>
            <ArticleId IdType="pmc">5464605</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villeneuve NF, Sun Z, Chen W, Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell Cycle. 2009;8:3255–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19806015</ArticleId>
            <ArticleId IdType="pmc">3918967</ArticleId>
            <ArticleId IdType="doi">10.4161/cc.8.20.9565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Sun Z, Wang X-J, Jiang T, Huang Z, Fang D, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009;34:663–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19560419</ArticleId>
            <ArticleId IdType="pmc">2714804</ArticleId>
            <ArticleId IdType="doi">10.1016/j.molcel.2009.04.029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, et al. The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal. 2014;21:2498–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24892215</ArticleId>
            <ArticleId IdType="pmc">4245871</ArticleId>
            <ArticleId IdType="doi">10.1089/ars.2014.5843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21734707</ArticleId>
            <ArticleId IdType="pmc">3404470</ArticleId>
            <ArticleId IdType="doi">10.1038/nature10189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayers D, Baron B, Hunter T. miRNA Influences in NR F2 Pathway I. J Nucleic Acids. 2015;2015: e143636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/143636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris SAL, Huang S. Crosstalk of the Wnt/β-catenin pathway with other pathways in cancer cells. Genes Dis. 2016;3:41–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27081668</ArticleId>
            <ArticleId IdType="pmc">4828918</ArticleId>
            <ArticleId IdType="doi">10.1016/j.gendis.2015.12.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collu GM, Hidalgo-Sastre A, Brennan K. Wnt-Notch signalling crosstalk in development and disease. Cell Mol Life Sci. 2014;71:3553–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24942883</ArticleId>
            <ArticleId IdType="doi">10.1007/s00018-014-1644-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Remark LH, Josephson AM, Leclerc K, Lopez EM, Kirby DJ, et al. Notch-Wnt signal crosstalk regulates proliferation and differentiation of osteoprogenitor cells during intramembranous bone healing. NPJ Regen Med. 2021;6:29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34050174</ArticleId>
            <ArticleId IdType="pmc">8163848</ArticleId>
            <ArticleId IdType="doi">10.1038/s41536-021-00139-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakabayashi N, Chartoumpekis DV, Kensler TW. Crosstalk between Nrf2 and Notch signaling. Free Radic Biol Med. 2015;88:158–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26003520</ArticleId>
            <ArticleId IdType="pmc">4628857</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.05.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparaneo A, Fabrizio FP, Muscarella LA. Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad [Internet]. Oxidative Medicine and Cellular Longevity. Hindawi; 2016 [cited 2020 Sep 3]. p. e7316492. Available from: https://www.hindawi.com/journals/omcl/2016/7316492/</Citation>
        </Reference>
        <Reference>
          <Citation>Polvani S, Tarocchi M, Galli A. PPAR and Oxidative Stress: Con(β) Catenating NRF2 and FOXO. PPAR Res. 2012;2012:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/641087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowland MA, Greenbaum JM, Deeds EJ. Crosstalk and the evolvability of intracellular communication. Nat Commun. 2017;8:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms16009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acar A, Hidalgo-Sastre A, Leverentz MK, Mills C, Woodcock S, Baron M, et al. Inhibition of Wnt signalling by Notch via two distinct mechanisms. Sci Rep. 2021;11:1–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-88618-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieiro D, Rios AC, Hirst CE, Marcelle C. Cytoplasmic NOTCH and membrane-derived β-catenin link cell fate choice to epithelial-mesenchymal transition during myogenesis. eLife. 5:e14847.</Citation>
        </Reference>
        <Reference>
          <Citation>Collu GM, Hidalgo-Sastre A, Acar A, Bayston L, Gildea C, Leverentz MK, et al. Dishevelled limits Notch signalling through inhibition of CSL. Development. 2012;139:4405–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23132247</ArticleId>
            <ArticleId IdType="pmc">3509734</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.081885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ungerbäck J, Elander N, Grünberg J, Sigvardsson M, Söderkvist P. The Notch-2 gene is regulated by Wnt signaling in cultured colorectal cancer cells. PLoS One. 2011;6(3):e17957.  https://doi.org/10.1371/journal.pone.0017957 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0017957</ArticleId>
            <ArticleId IdType="pubmed">21437251</ArticleId>
            <ArticleId IdType="pmc">3060910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/β-catenin but not bone morphogenetic protein signaling. J Biol Chem. 2006;281:6203–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16407293</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M508370200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galceran J, Sustmann C, Hsu S-C, Folberth S, Grosschedl R. LEF1-mediated regulation of Delta-like1 links Wnt and Notch signaling in somitogenesis. Genes Dev. 2004;18:2718–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15545629</ArticleId>
            <ArticleId IdType="pmc">528889</ArticleId>
            <ArticleId IdType="doi">10.1101/gad.1249504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Issack PS, Ziff EB. Genetic elements regulating HES-1 induction in Wnt-1-transformed PC12 cells. Cell Growth Differ. 1998;9:827–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9790494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Jia Z, Wang T, Wang W, Zhang C, Chen P, et al. Interaction of Wnt/β-catenin and notch signaling in the early stage of cardiac differentiation of P19CL6 cells. J Cell Biochem. 2012;113:629–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21956839</ArticleId>
            <ArticleId IdType="doi">10.1002/jcb.23390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borggrefe T, Lauth M, Zwijsen A, Huylebroeck D, Oswald F, Giaimo BD. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. Biochim Biophys Acta. 2016;1863:303–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26592459</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2015.11.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakabayashi N, Skoko JJ, Chartoumpekis DV, Kimura S, Slocum SL, Noda K, et al. Notch-Nrf2 Axis: Regulation of Nrf2 Gene Expression and Cytoprotection by Notch Signaling. Mol Cell Biol. 2014;34:653–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24298019</ArticleId>
            <ArticleId IdType="pmc">3911489</ArticleId>
            <ArticleId IdType="doi">10.1128/MCB.01408-13</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannan S, Zweidler-McKay PA. A Novel Notch/NRF2 mechanism mediates reductive stress in acute myeloblastic leukemia (AML): a therapeutic strategy to overcome chemoresistance. Blood. 2015;126:4834–4834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V126.23.4834.4834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan H, Sun Z. Abstract A50: Nrf2 regulates cellular behaviors and Notch signaling in oral squamous cell carcinoma cells in vivo and in vitro. Cancer Res. 2018;78:A50–A50.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Q, Mao A, Yan J, Sun C, Di C, Zhou X, et al. Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells. Int J Oncol. 2016;48:765–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26691854</ArticleId>
            <ArticleId IdType="doi">10.3892/ijo.2015.3301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H-S, Zhang Z-G, Du G-Y, Sun H-L, Liu H-Y, Zhou Z, et al. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1α/Notch1 axis. J Cell Mol Med. 2019;23:3451–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30809937</ArticleId>
            <ArticleId IdType="pmc">6484400</ArticleId>
            <ArticleId IdType="doi">10.1111/jcmm.14241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brigelius-Flohé R, Kipp AP. Chapter Four - Selenium in the Redox Regulation of the Nrf2 and the Wnt Pathway. In: Cadenas E, Packer L, editors. Methods in Enzymology [Internet]. Academic Press; 2013 [cited 2020 Sep 4]. p. 65–86. Available from: http://www.sciencedirect.com/science/article/pii/B9780124058828000040</Citation>
        </Reference>
        <Reference>
          <Citation>Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21245377</ArticleId>
            <ArticleId IdType="pmc">3067901</ArticleId>
            <ArticleId IdType="doi">10.1128/MCB.01204-10</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol. 2012;32:3486–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22751928</ArticleId>
            <ArticleId IdType="pmc">3422007</ArticleId>
            <ArticleId IdType="doi">10.1128/MCB.00180-12</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L. ERK/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med [Internet]. 2020 [cited 2021 Oct 5]; Available from: http://www.spandidos-publications.com/ https://doi.org/10.3892/etm.2020.8454</Citation>
        </Reference>
        <Reference>
          <Citation>Su C-M, Su Y-H, Chiu C-F, Chang Y-W, Hong C-C, Yu Y-H, et al. Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21:767–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-014-4009-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng S, Liu T, Middottuersun A, Huo Q, Liu Q, Huang C, et al. [Expression of ERK1/2 MAPK signaling transduction pathway in esophageal cancers in Kazakh patients]. Zhonghua Zhong Liu Za Zhi. 2011;33:421–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, et al. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Therapeut AACR. 2008;7:2866–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-08-0391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina JR, Adjei AA. The Ras/Raf/MAPK Pathway. J Thorac Oncol. 2006;1:7–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409820</ArticleId>
            <ArticleId IdType="doi">10.1016/S1556-0864(15)31506-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24202392</ArticleId>
            <ArticleId IdType="pmc">4049336</ArticleId>
            <ArticleId IdType="doi">10.1038/nm.3388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. N Engl J Med. 2008;358:1160–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18337605</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMra0707704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbaszadegan MR, Riahi A, Forghanifard MM, Moghbeli M. WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma. Cell Mol Biol Lett. 2018;23:42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30202417</ArticleId>
            <ArticleId IdType="pmc">6122622</ArticleId>
            <ArticleId IdType="doi">10.1186/s11658-018-0109-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y-M, Hong P, Xu WW, He Q-Y, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32296011</ArticleId>
            <ArticleId IdType="pmc">6946647</ArticleId>
            <ArticleId IdType="doi">10.1038/s41392-019-0089-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassan MS, Makuru V, von Holzen U. Targeted therapy in esophageal cancer. Dig Med Res. 2021;4:29–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/dmr-21-16</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC, VanSluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008;111:2647–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17993608</ArticleId>
            <ArticleId IdType="pmc">2254536</ArticleId>
            <ArticleId IdType="doi">10.1182/blood-2007-08-109710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling ? in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633338</ArticleId>
            <ArticleId IdType="doi">10.1038/nrm1911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg. 2001;88:1105–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11488797</ArticleId>
            <ArticleId IdType="doi">10.1046/j.0007-1323.2001.01838.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozlowski M, Kowalczuk O, Milewski R, Chyczewski L, Niklinski J, Laudański J. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg. 2010;38:260–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20226684</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejcts.2010.01.061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>XU W, Li B, Cheung A. The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer. Gastrointest Cancer. 2015;5:79–88.</Citation>
        </Reference>
        <Reference>
          <Citation>Li B, Xu WW, Lam AKY, Wang Y, Hu H-F, Guan XY, et al. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget. 2017;8:38755–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28418888</ArticleId>
            <ArticleId IdType="pmc">5503569</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.16333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S-Q, Wang X, Zheng K, Liu K-S, Wang S-X, Xie C-H. Simultaneous targeting PI3K and PERK pathways promotes cell death and improves the clinical prognosis in esophageal squamous carcinoma. Biochem Biophys Res Commun. 2017;493:534–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28867195</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.08.156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018;8:608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30631751</ArticleId>
            <ArticleId IdType="pmc">6315195</ArticleId>
            <ArticleId IdType="doi">10.3389/fonc.2018.00608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Pan J. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells: ESCC cells are sensitive to CDK4/6 inhibition. Br J Pharmacol. 2017;174:2427–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28444744</ArticleId>
            <ArticleId IdType="pmc">5513862</ArticleId>
            <ArticleId IdType="doi">10.1111/bph.13836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong T, Wang M, Zhao J, Liu Q, Yang C, Luo W, et al. An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy. Oncotarget. 2017;8:49851–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28591712</ArticleId>
            <ArticleId IdType="pmc">5564812</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.17989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier M, Li X, de Silva N, Eldridge MD, Contino G, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48:1131–41.</Citation>
        </Reference>
        <Reference>
          <Citation>Miyamoto K, Minegaki T, Tanahashi M, Yamamoto A, Moriyama Y, Wada A, et al. Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines. Anticancer Res. 2019;39:1813–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30952721</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol. 2020;43:195–209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13402-019-00488-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci. 2000;113:4313–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11069775</ArticleId>
            <ArticleId IdType="doi">10.1242/jcs.113.23.4313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, Di Serio C, et al. Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype. J Biol Chem. 2001;276:32022–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11427524</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M100933200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds ND, Lukacs NW, Long N, Karpus WJ. Delta-like ligand 4 regulates central nervous system T cell accumulation during experimental autoimmune encephalomyelitis. J Immunol. 2011;187:2803–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21788444</ArticleId>
            <ArticleId IdType="doi">10.4049/jimmunol.1100160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith DC, Chugh R, Patnaik A, Papadopoulos KP, Wang M, Kapoun AM, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. Invest New Drugs. 2019;37:722–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30591982</ArticleId>
            <ArticleId IdType="doi">10.1007/s10637-018-0714-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol Mech Dis. 2008;3:587–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pathmechdis.3.121806.154300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012;134:495–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22547109</ArticleId>
            <ArticleId IdType="pmc">4545650</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-012-2075-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20068161</ArticleId>
            <ArticleId IdType="pmc">3442245</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, et al. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res. 2012;18:5008–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22806875</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, et al. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016;56:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26798966</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.11.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng J, Wang J, Liu Q, Li J, Zhang Q, Zhuang Z, et al. DAPT, a γ-secretase inhibitor, suppresses tumorigenesis and progression of growth hormone-producing adenomas by targeting Notch signaling. Front Oncol. 2019;9:809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31508369</ArticleId>
            <ArticleId IdType="pmc">6718711</ArticleId>
            <ArticleId IdType="doi">10.3389/fonc.2019.00809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14709552</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M311652200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry. 2000;39:8698–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10913280</ArticleId>
            <ArticleId IdType="doi">10.1021/bi0005456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groth C, Alvord WG, Quinones OA, Fortini ME. Pharmacological analysis of Drosophila melanogaster γ-secretase with respect to differential proteolysis of Notch and APP. Mol Pharmacol. 2010;77:567–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20064975</ArticleId>
            <ArticleId IdType="pmc">2845938</ArticleId>
            <ArticleId IdType="doi">10.1124/mol.109.062471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, et al. Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. Biol Chem. 2017;292:837–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.745208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrarotto R, Ho AL, Wirth LJ, Dekel E, Walker RW, Vergara-Silva AL. ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut). J Clin Oncol. 2019;37:TPS6098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.TPS6098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, et al. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther. 2017;16:2759–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28978720</ArticleId>
            <ArticleId IdType="pmc">5716926</ArticleId>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-17-0439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018;9:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-017-0012-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balakrishnan A, Patel B, Sieber SA, Chen D, Pachikara N, Zhong G, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006;281:16691–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16565079</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M513648200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slack BE, Ma LK, Seah CC. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme. Biochem J. 2001;357:787–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11463349</ArticleId>
            <ArticleId IdType="pmc">1222008</ArticleId>
            <ArticleId IdType="doi">10.1042/bj3570787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgiadis D, Yiotakis A. Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem Elsevier. 2008;16:8781–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmc.2008.08.058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoki K, Kondo Y, Naoki H, Hiratsuka T, Itoh RE, Matsuda M. Propagating wave of ERK activation orients collective cell migration. Dev Cell. 2017;43:305–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29112851</ArticleId>
            <ArticleId IdType="doi">10.1016/j.devcel.2017.10.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, et al. Identification and characterization of 4-[[4-(2-butynyloxy) phenyl] sulfonyl]-N-hydroxy-2, 2-dimethyl-(3S) thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther. 2004;309:348–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14718605</ArticleId>
            <ArticleId IdType="doi">10.1124/jpet.103.059675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehal R, Urech C, Vigolo M, Murone M, Radtke F. Characterization and profiling of CB-103, a novel small-molecule protein-protein interaction inhibitor targeting the NOTCH transcription complex. AACR; 2018;5799.</Citation>
        </Reference>
        <Reference>
          <Citation>Perron A, Nishikawa Y, Iwata J, Shimojo H, Takaya J, Kobayashi K, et al. Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone. J Biol Chem. 2018;293:8285–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29523683</ArticleId>
            <ArticleId IdType="pmc">5971435</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.RA118.002316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Khoueiry AB, Desai J, Iyer SP, Gadgeel SM, Ramalingam SS, Horn L, et al. A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors. Am J Clin Oncol. 2018;36:2515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.2515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massard C, Azaro A, Soria J-C, Lassen U, Le Tourneau C, Sarker D, et al. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol. 2018;29:1911–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30060061</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdy244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21:60–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25231399</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30:2348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22529266</ArticleId>
            <ArticleId IdType="pmc">5950496</ArticleId>
            <ArticleId IdType="doi">10.1200/JCO.2011.36.8282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012;48:997–1003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22445247</ArticleId>
            <ArticleId IdType="pmc">4522922</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejca.2012.02.056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho SY, Keller TH. The use of porcupine inhibitors to target Wnt-driven cancers. Bioorg Med Chem Lett. 2015;25:5472–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26522946</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bmcl.2015.10.032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Wu G, Xu Y, Li J, Ruan N, Chen Y, et al. Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma. BioMed Res Int. 2020;2020:2527643</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32104684</ArticleId>
            <ArticleId IdType="pmc">7040395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang J, Lan C, Li L, Yang D, Xia X, Liao Q, et al. A novel porcupine inhibitor blocks WNT pathways and attenuates cardiac hypertrophy. Biochim Biophys Acta Mol Basis Dis. 2018;1864:3459–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30076960</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbadis.2018.07.035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan C-W, et al. Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5:100–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19125156</ArticleId>
            <ArticleId IdType="pmc">2628455</ArticleId>
            <ArticleId IdType="doi">10.1038/nchembio.137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang SMA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19759537</ArticleId>
            <ArticleId IdType="doi">10.1038/nature08356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation–driven colorectal tumor growth. Cancer Res. 2013;73:3132–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23539443</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, et al. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23621985</ArticleId>
            <ArticleId IdType="pmc">3644501</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2407-13-211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS ONE. 2012;7: e48670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23144924</ArticleId>
            <ArticleId IdType="pmc">3492487</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0048670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D, Koh B, Kim KR, Kim KY, Jung WH, Kim HY, et al. Anticancer effect of XAV939 is observed by inhibiting lactose dehydrogenase A in a 3-dimensional culture of colorectal cancer cells. Oncology Lett. 2019;18:4858–64.</Citation>
        </Reference>
        <Reference>
          <Citation>Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, et al. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016;7:28273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27070088</ArticleId>
            <ArticleId IdType="pmc">5053726</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.8626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, et al. AZ1366: an inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin Cancer Res. 2017;23:1531–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27663586</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-1179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voronkov A, Holsworth DD, Waaler J, Wilson SR, Ekblad B, Perdreau-Dahl H, et al. Structural basis and SAR for G007-LK, a lead stage 1, 2, 4-triazole based specific tankyrase 1/2 inhibitor. J Med Chem. 2013;56:3012–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23473363</ArticleId>
            <ArticleId IdType="doi">10.1021/jm4000566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72:2822–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22440753</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-3336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong H-C, Bourdelas A, Krauss A, Lee H-J, Shao Y, Wu D, et al. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol cell. 2003;12:1251–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14636582</ArticleId>
            <ArticleId IdType="pmc">4381837</ArticleId>
            <ArticleId IdType="doi">10.1016/S1097-2765(03)00427-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Dai J, Sun Z, Shi C, Cao H, Chen X, et al. Targeted inhibition of disheveled PDZ domain via NSC668036 depresses fibrotic process. Exp Cell Res. 2015;331:115–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25445788</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2014.10.023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shan J, Zhang X, Bao J, Cassell R, Zheng JJ. Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies. Chem Biol Drug Des. 2012;79:376–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172211</ArticleId>
            <ArticleId IdType="pmc">3310947</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1747-0285.2011.01295.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepourcelet M, Chen YNP, France DS, Wang H, Crews P, Petersen F, et al. Gandhirajan. Cancer Cell. 2004;5:91–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14749129</ArticleId>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00334-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandhirajan R, Gehrke I, Plickert G, Schlösser A, Schmitt E, Hallek M, et al. Abstract# 1920: CGP049090 and PKF115–584 selectively induce apoptosis of CLL cells in vitro and in vivo by inhibition of beta-catenin/lef-1 signaling. AACR; 2009;1920.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei W, Chua M-S, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009;8:1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, et al. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Therapeut AACR. 2014;13:2303–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-1005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13:4042–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17634527</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-2316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee E, Madar A, David G, Garabedian MJ, DasGupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci USA. 2013;110:15710–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24019458</ArticleId>
            <ArticleId IdType="pmc">3785716</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1218168110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA. 2011;108:5954–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21393571</ArticleId>
            <ArticleId IdType="pmc">3076864</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1017496108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang GB, Hong IS, Kim RJ, Lee SY, Park SJ, Lee ES, et al. Wnt/b-catenin small molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells. Cancer Res. 2015;75:1691–702</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25660951</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J-Y, Lee H-Y, Park K-K, Choi Y-K, Nam J-S, Hong I-S. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. Oncotarget. 2016;7:20395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26967248</ArticleId>
            <ArticleId IdType="pmc">4991463</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.7954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwak J, Hwang SG, Park H-S, Choi SR, Park S-H, Kim H, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. Cell Res. 2012;22:237–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21826110</ArticleId>
            <ArticleId IdType="doi">10.1038/cr.2011.127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, et al. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29:1267–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25482131</ArticleId>
            <ArticleId IdType="doi">10.1038/leu.2014.340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simonetta KR, Taygerly J, Boyle K, Basham SE, Padovani C, Lou Y, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat Commun. 2019;10:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09358-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fong Y, Tang CC, Hu HT, Fang HY, Chen BH, Wu CY, et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin Med. 2016;11:45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27733866</ArticleId>
            <ArticleId IdType="pmc">5045596</ArticleId>
            <ArticleId IdType="doi">10.1186/s13020-016-0116-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Mook RA Jr, Ren XR, et al. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. Bioorg Med Chem. 2018;26:5435–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30274939</ArticleId>
            <ArticleId IdType="pmc">6688896</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bmc.2018.09.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon R, Hong H, Wei X, Pan J, Alman BA. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS ONE. 2012;7: e37940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22666417</ArticleId>
            <ArticleId IdType="pmc">3364163</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0037940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olayanju A, Copple IM, Bryan HK, Edge GT, Sison RL, Wong MW, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015;78:202–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25445704</ArticleId>
            <ArticleId IdType="pmc">4291150</ArticleId>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.11.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai SJ, Liu Y, Han S, Yang C. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci. 2019;9:1–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13578-019-0309-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Venkannagari S, Oh KH, Zhang Y-Q, Rohde JM, Liu L, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11:3214–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27552339</ArticleId>
            <ArticleId IdType="pmc">5367156</ArticleId>
            <ArticleId IdType="doi">10.1021/acschembio.6b00651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies TG, Wixted WE, Coyle JE, Griffiths-Jones C, Hearn K, McMenamin R, et al. Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2) protein–protein interaction with high cell potency identified by fragment-based discovery. J Med Chem. 2016;59:3991–4006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27031670</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b00228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang W-C, Liao Y-W, Chen P-N, Lu K-H, Yu C-C, Hsieh P-L. Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation. Cancer Chemother Pharmacol. 2017;80:411–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28685346</ArticleId>
            <ArticleId IdType="doi">10.1007/s00280-017-3381-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen X, Thorne G, Hu L, Joy MS, Aleksunes LM. Activation of NRF2 signaling in HEK293 cells by a first-in-class direct KEAP1-NRF2 inhibitor. Biochem Mol Toxicol. 2015;29:261–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbt.21693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Su L, Ye Q, Zhang S, Kung H, Jiang F, et al. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells. Oncotarget. 2017;8:7625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28032588</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.13825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu M-C, Zhang X, Wu F, Tan S-J, Zhao J, You Q-D, et al. Discovery of a potent Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1–Nrf2) protein–protein interaction inhibitor with natural proline structure as a cytoprotective agent against acetaminophen-induced hepatotoxicity. J Med Chem. 2019;62:6796–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31283229</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.9b00818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi EJ, Jung BJ, Lee SH, Yoo HS, Shin EA, Ko HJ, et al. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Oncogene. 2017;36:5285–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28504720</ArticleId>
            <ArticleId IdType="doi">10.1038/onc.2017.153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollong MJ, Yun H, Sherwood L, Woods AK, Lairson LL, Schultz PG. A small molecule inhibits deregulated NRF2 transcriptional activity in cancer. ACS Chem Biol. 2015;10:2193–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26270491</ArticleId>
            <ArticleId IdType="doi">10.1021/acschembio.5b00448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duong H-Q, Yi YW, Kang HJ, Hong YB, Tang W, Wang A, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 2014;44:959–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24366069</ArticleId>
            <ArticleId IdType="doi">10.3892/ijo.2013.2229</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
